Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
26
APRE Quote, Financials, Valuation and Earnings
Last price:
$0.91
Seasonality move
:
-7.02%
Day range:
$0.91 - $0.94
52-week range:
$0.90 - $5.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
11.37x
P/B ratio:
0.53x
Volume:
59.6K
Avg. volume:
78.3K
1-year change:
-70.45%
Market cap:
$5.7M
Revenue:
$1.5M
EPS (TTM):
-$2.14
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
APRE
Aprea Therapeutics, Inc.
|
-- | -$0.10 | -100% | -84.3% | $10.50 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.20 | -- | -26.67% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
APRE
Aprea Therapeutics, Inc.
|
$0.91 | $10.50 | $5.7M | -- | $0.00 | 0% | 11.37x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$2.95 | $0.85 | $371.7M | 4.96x | $0.80 | 0% | 5.73x |
|
NNVC
NanoViricides, Inc.
|
$1.21 | $6.50 | $21.8M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.82 | $2.00 | $678.8K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.18 | $7.00 | $5.9M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
APRE
Aprea Therapeutics, Inc.
|
-- | 1.666 | -- | 5.12x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
APRE
Aprea Therapeutics, Inc.
|
-$3.6K | -$3.1M | -75.35% | -75.35% | -173188.89% | -$3.3M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Aprea Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns APRE or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -165133.33% compared to Aprea Therapeutics, Inc.'s net margin of -255.85%. Aprea Therapeutics, Inc.'s return on equity of -75.35% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital APREAprea Therapeutics, Inc.-200% -$0.47 $11.6M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About APRE or NBY?
Aprea Therapeutics, Inc. has a consensus price target of $10.50, signalling upside risk potential of 1053.72%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -71.19%. Given that Aprea Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Aprea Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APREAprea Therapeutics, Inc.1 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is APRE or NBY More Risky?
Aprea Therapeutics, Inc. has a beta of 1.229, which suggesting that the stock is 22.931% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock APRE or NBY?
Aprea Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Aprea Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APRE or NBY?
Aprea Therapeutics, Inc. quarterly revenues are $1.8K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Aprea Therapeutics, Inc.'s net income of -$3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Aprea Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 4.96x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aprea Therapeutics, Inc. is 11.37x versus 5.73x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APREAprea Therapeutics, Inc.11.37x -- $1.8K -$3M NBYNovaBay Pharmaceuticals, Inc.5.73x 4.96x $521K -$1.3M
-
Which has Higher Returns APRE or NNVC?
NanoViricides, Inc. has a net margin of -165133.33% compared to Aprea Therapeutics, Inc.'s net margin of --. Aprea Therapeutics, Inc.'s return on equity of -75.35% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital APREAprea Therapeutics, Inc.-200% -$0.47 $11.6M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About APRE or NNVC?
Aprea Therapeutics, Inc. has a consensus price target of $10.50, signalling upside risk potential of 1053.72%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 437.19%. Given that Aprea Therapeutics, Inc. has higher upside potential than NanoViricides, Inc., analysts believe Aprea Therapeutics, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APREAprea Therapeutics, Inc.1 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is APRE or NNVC More Risky?
Aprea Therapeutics, Inc. has a beta of 1.229, which suggesting that the stock is 22.931% more volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock APRE or NNVC?
Aprea Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aprea Therapeutics, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APRE or NNVC?
Aprea Therapeutics, Inc. quarterly revenues are $1.8K, which are larger than NanoViricides, Inc. quarterly revenues of --. Aprea Therapeutics, Inc.'s net income of -$3M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Aprea Therapeutics, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aprea Therapeutics, Inc. is 11.37x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APREAprea Therapeutics, Inc.11.37x -- $1.8K -$3M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns APRE or OGEN?
Oragenics, Inc. has a net margin of -165133.33% compared to Aprea Therapeutics, Inc.'s net margin of --. Aprea Therapeutics, Inc.'s return on equity of -75.35% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital APREAprea Therapeutics, Inc.-200% -$0.47 $11.6M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About APRE or OGEN?
Aprea Therapeutics, Inc. has a consensus price target of $10.50, signalling upside risk potential of 1053.72%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 142.45%. Given that Aprea Therapeutics, Inc. has higher upside potential than Oragenics, Inc., analysts believe Aprea Therapeutics, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APREAprea Therapeutics, Inc.1 0 0 OGENOragenics, Inc.1 0 0 -
Is APRE or OGEN More Risky?
Aprea Therapeutics, Inc. has a beta of 1.229, which suggesting that the stock is 22.931% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock APRE or OGEN?
Aprea Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aprea Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APRE or OGEN?
Aprea Therapeutics, Inc. quarterly revenues are $1.8K, which are larger than Oragenics, Inc. quarterly revenues of --. Aprea Therapeutics, Inc.'s net income of -$3M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Aprea Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aprea Therapeutics, Inc. is 11.37x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APREAprea Therapeutics, Inc.11.37x -- $1.8K -$3M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns APRE or PTN?
Palatin Technologies has a net margin of -165133.33% compared to Aprea Therapeutics, Inc.'s net margin of --. Aprea Therapeutics, Inc.'s return on equity of -75.35% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital APREAprea Therapeutics, Inc.-200% -$0.47 $11.6M PTNPalatin Technologies-- -- -- -
What do Analysts Say About APRE or PTN?
Aprea Therapeutics, Inc. has a consensus price target of $10.50, signalling upside risk potential of 1053.72%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Aprea Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Aprea Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APREAprea Therapeutics, Inc.1 0 0 PTNPalatin Technologies0 0 0 -
Is APRE or PTN More Risky?
Aprea Therapeutics, Inc. has a beta of 1.229, which suggesting that the stock is 22.931% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock APRE or PTN?
Aprea Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aprea Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APRE or PTN?
Aprea Therapeutics, Inc. quarterly revenues are $1.8K, which are larger than Palatin Technologies quarterly revenues of --. Aprea Therapeutics, Inc.'s net income of -$3M is higher than Palatin Technologies's net income of --. Notably, Aprea Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aprea Therapeutics, Inc. is 11.37x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APREAprea Therapeutics, Inc.11.37x -- $1.8K -$3M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns APRE or TOVX?
Theriva Biologics, Inc. has a net margin of -165133.33% compared to Aprea Therapeutics, Inc.'s net margin of --. Aprea Therapeutics, Inc.'s return on equity of -75.35% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital APREAprea Therapeutics, Inc.-200% -$0.47 $11.6M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About APRE or TOVX?
Aprea Therapeutics, Inc. has a consensus price target of $10.50, signalling upside risk potential of 1053.72%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3897.72%. Given that Theriva Biologics, Inc. has higher upside potential than Aprea Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Aprea Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings APREAprea Therapeutics, Inc.1 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is APRE or TOVX More Risky?
Aprea Therapeutics, Inc. has a beta of 1.229, which suggesting that the stock is 22.931% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock APRE or TOVX?
Aprea Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aprea Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios APRE or TOVX?
Aprea Therapeutics, Inc. quarterly revenues are $1.8K, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Aprea Therapeutics, Inc.'s net income of -$3M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Aprea Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aprea Therapeutics, Inc. is 11.37x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income APREAprea Therapeutics, Inc.11.37x -- $1.8K -$3M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 59x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
35
SMX alert for Dec 19
SMX (Security Matters) Plc [SMX] is up 24.85% over the past day.
Sell
36
INSP alert for Dec 19
Inspire Medical Systems, Inc. [INSP] is down 19.66% over the past day.
Sell
40
INSM alert for Dec 19
Insmed, Inc. [INSM] is down 16.08% over the past day.
